Medicamento de edição genética reduz colesterol ruim em 62 por cento em estudo

28 de maio de 2026

Reportado por IA

Uma terapia experimental chamada VERVE-102 reduziu o colesterol LDL em até 62 por cento após uma única dose em um estudo inicial de segurança. Os resultados vêm de um ensaio de Fase I envolvendo 35 pacientes com colesterol alto ou doença cardiovascular precoce. Os dados foram publicados esta semana no New England Journal of Medicine.

Os pesquisadores relataram que o tratamento pareceu seguro, sem efeitos colaterais graves, mesmo na dose mais alta. Os participantes apresentaram apenas um aumento leve e temporário nas enzimas hepáticas. O medicamento utiliza mRNA encapsulado em nanopartículas para editar o gene PCSK9 nas células do fígado, reduzindo permanentemente a produção de uma proteína que eleva os níveis de LDL.

UT Southwestern researchers identify HELZ2 protein that controls the liver’s release of cholesterol-carrying particles

25 de maio de 2026 Reportado por IA Imagem gerada por IA Verificado

Scientists at UT Southwestern Medical Center report they have identified a protein, HELZ2, that acts as a key regulator of how many cholesterol-carrying particles the liver releases into the bloodstream by affecting the gene APOB. The study was published in the American Heart Association journal Circulation and could inform future research into heart disease and fatty liver disease.

Enlicitide pill reduces LDL cholesterol by 60% in phase 3 trial

An experimental oral pill called enlicitide lowered LDL cholesterol by about 60% in a large phase three clinical trial, according to results published in The New England Journal of Medicine. The trial, led by Dr. Ann Marie Navar at UT Southwestern Medical Center and sponsored by Merck, involved 2,909 participants mostly already on statins. If approved, the daily pill could improve access to effective cholesterol treatment.

DNA hairpin molecules lowered cholesterol by 47% in mice by silencing PCSK9, researchers report

01 de maio de 2026 Reportado por IA Verificado

Researchers from the University of Barcelona and the University of Oregon report that short DNA molecules known as polypurine reverse Hoogsteen hairpins (PPRHs) suppressed the PCSK9 gene and reduced blood cholesterol in a mouse model. In transgenic mice carrying the human PCSK9 gene, a single injection of one candidate (HpE12) cut plasma PCSK9 by 50% and total cholesterol by 47% three days later, according to findings published in Biochemical Pharmacology.

Saúde

Virus injection halts pancreatic tumor growth in trial

Saúde

UCLA scientists reverse liver damage in mice by removing zombie cells

Saúde

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

Compound X clears Parkinson's proteins in mice brains

Researchers in Australia have found that a mysterious FDA-approved drug, called compound X, removes toxic alpha-synuclein proteins from the brains of mice with Parkinson's-like symptoms. The treatment improved the animals' balance and mobility by enhancing the brain's glymphatic waste disposal system. The findings were presented at a symposium in the UK.

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

21 de maio de 2026 Reportado por IA Verificado

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

terça-feira, 26 de maio de 2026, 14:54h